GHRH analogue comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
=== Fast === Fast COLD-PCR differs from Full COLD-PCR in that the denaturation and intermediate annealing stages are skipped. This is because, in some cases, the preferential amplification of the mutant DNA is so great that ensuring the formation of the mutant/wildtype heteroduplex DNA is not needed. Thus the denaturation can occur at the Tc, proceed to primer annealing, and then polymerase-mediated extension. Each round of amplification will include these three stages in that order. By utilizing the lower denaturation temperature, the reaction will discriminate toward the products with the lower Tm – i.e. the variant alleles. Fast COLD-PCR produces much faster results due to the shortened protocol, while Full COLD-PCR is essential for amplification of all possible mutations in the starting mixture of DNA. Two-round COLD-PCR is a modified version of Fast COLD-PCR. During the second round of Fast COLD-PCR nested primers are used. This improves the sensitivity of mutation detection compared to one-round Fast COLD-PCR.
After being elected in November 2024, Trump said he wished to end the Gaza war, telling Israeli prime minister Benjamin Netanyahu to end Israel's invasion within two months and warning Hamas that they would have "all hell to pay" if they did not agree to a ceasefire and release all hostages by Trump's inauguration. Trump's incoming administration joined the Biden administration in pressuring negotiations, and Israel and Hamas agreed to a phased ceasefire on January 15, 2025. In February 2025, Trump proposed an American takeover of Gaza in which the territory's Palestinian population would be relocated to allow for its redevelopment, which was criticized by Egypt and Jordan. The ceasefire lasted until March 18, when Israel launched attacks on Gaza. Trump's special envoy Steve Witkoff blamed Hamas for renewed fighting in Gaza. On May 16, while in Abu Dhabi, United Arab Emirates, Trump said, "We're looking at Gaza. And we're going to get that taken care of. A lot of people are starving." This is an area of tension between President Trump and Prime Minister Benjamin Netanyahu. Israel claims that Hamas systemically raids food aid in order to support its operations, and Israel has put forward a plan of food distributed through a system of hubs run by private contractors and protected by Israeli soldiers. The U.S.-backed Gaza Humanitarian Foundation has been set up to carry out this plan and announced it would be ready to begin operations by the end of May. On July 28, while in Scotland, President Trump said he believed there was starvation occurring in Gaza.
Hexapeptide-10 (SIKVAV, Serilesine) is a hexapeptide that is composed of a sequence Ser-Ile-Lys-Val-Ala-Val found at the C-terminus of the laminin α1 chain. Unlike other matrikine peptides which primarily act in the epidermis, hexapeptide-10 is active in deeper skin layers and promotes synthesis of laminin and integrin proteins, increases secretion of matrix metalloproteinases MMP2 and MMP9, and has angiogenic effects. Hexapeptide-10 promotes wound healing and tissue remodeling, and is used in skincare products with purported anti-aging effects. It has also been investigated for potential medical applications in the treatment of conditions such as Alzheimer's disease and muscular dystrophy. Due to its ability to promote angiogenesis, it can also promote tumour growth and is used in cancer research, though this requires concentrations many times higher than those used in skincare products.
A tire-pressure monitoring system (TPMS) monitors the air pressure inside the pneumatic tires on vehicles. As a form of vehicle telematics, a TPMS reports real-time tire-pressure information to the driver, using either a gauge, a pictogram display, or a simple low-pressure warning light. TPMS can be divided into two different types – direct (dTPMS) and indirect (iTPMS). TPMS are installed either when the vehicle is made or after the vehicle is put to use. The goal of a TPMS, as a component in a wider intelligent transportation system, is avoiding traffic accidents, poor fuel economy, and increased tire wear due to under-inflated tires through early recognition of a hazardous state of the tires. This functionality first appeared in luxury vehicles in Europe in the 1980s, while mass-market adoption followed the USA passing the 2000 TREAD Act after the Firestone and Ford tire controversy. Mandates for TPMS technology in new cars have continued to proliferate in the 21st century in Russia, the EU, Japan, South Korea and many other Asian countries. From November 2014 TPMS was mandatory for new vehicles in the European Union; in a survey carried out between November 2016 and August 2017, 54% of passenger cars in Sweden, Germany, and Spain were found not to have TPMS, a figure believed to be an under-estimate. Aftermarket valve cap-based dTPMS systems, which require a smartphone and an app or portable display unit, are also available for bicycles, automobiles, and trailers.
== Mechanics of Micronization == The size reduction achieved by mechanical micronization depends on both the mill and the material being ground. The breakage behaviour of a material can be characterised by material parameters derived from single-particle impact tests, which quantify a particle's resistance to fracture and the minimum specific energy it can absorb without breaking; these allow the breakage probability of different materials to be described by a common master curve.
Sources: en.wikipedia.org
The two substrates of this enzyme are (S)-dihydroorotic acid and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are orotic acid, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-CH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (S)-dihydroorotate:NAD+ oxidoreductase. This enzyme is also called orotate reductase (NADH). This enzyme participates in pyrimidine metabolism. It has 2 cofactors: flavin adenine dinucleotide, and flavin mononucleotide.
Pollard MR, Anderson L, Fan C, Hawkins DJ, Davies HM (1991). "A specific acyl-ACP thioesterase implicated in medium-chain fatty acid production in immature cotyledons of Umbellularia californica". Arch. Biochem. Biophys. 284 (2): 306–12. doi:10.1016/0003-9861(91)90300-8. PMID 1989513. Davies HM, Anderson L, Fan C, Hawkins DJ (1991). "Developmental induction, purification, and further characterization of 12:0-ACP thioesterase from immature cotyledons of Umbellularia californica". Arch. Biochem. Biophys. 290 (1): 37–45. doi:10.1016/0003-9861(91)90588-A. PMID 1898097.
=== Ongoing renewal of the Special Diabetes Program === Breakthrough T1D has been supporting the "Special Diabetes Program" (SDP) for 25 years. The program, which receives over $150 million in federal funding per year, provides resources and support for T1D research in cooperation with the NIH. Breakthrough T1D works with the U.S. Senate Diabetes Caucus to advocate for continued funding of the program, which also benefits Breakthrough T1D's research efforts.
== Further reading == Havelock, H. (April 1898). "The Cossacks in the Early Seventeenth Century". English Historical Review. 13 (50): 242–260. JSTOR 547225. Longworth, Philip (1969). The Cossacks. London: Constable. Seaton, Albert (1985). The Horsemen of the Steppes: The Story of the Cossacks. London: The Bodley Head. ISBN 978-0-370-30534-9. Summerfield, Stephen (2005). Cossack Hurrah: Russian Irregular Cavalry Organisation and Uniforms during the Napoleonic Wars. Partizan Press. ISBN 978-1-85818-513-2. Summerfield, Stephen (2007). The Brazen Cross: Brazen Cross of Courage: Russian Opochenie, Partizans and Russo-German Legion during the Napoleonic Wars. Partizan Press. ISBN 978-1-85818-555-2. Ure, John (1999). The Cossacks. London: Constable. ISBN 978-0-094-77400-1. Witzenrath, Christoph (2007). Cossacks and the Russian Empire, 1598–1725: Manipulation, Rebellion and Expansion into Siberia. Routledge. ISBN 978-1-134-11749-9. "General der Flieger Hellmuth Felmy" [The Cossack Corps]. US Army Historical Division. Hailer Publishing. 2007. Archived from the original on 2009-04-15. Kondufor, Yuri (1986). A Short History of the Ukraine. Kyiv: Naukova Dumka.
== Further reading == Barskov, I. S.; Boiko, M. S.; Konovalova, V. A.; Leonova, T. B.; Nikolaeva, S. V. (2008). "Cephalopods in the marine ecosystems of the Paleozoic". Paleontological Journal. 42 (11): 1167–1284. Bibcode:2008PalJ...42.1167B. doi:10.1134/S0031030108110014. S2CID 83608661. A comprehensive overview of Paleozoic cephalopods. Campbell, Neil A.; Reece, Jane B.; Mitchell, Lawrence G. (1999). Biology, fifth edition. Menlo Park, California: Addison Wesley Longman, Inc. ISBN 978-0-8053-6566-5. Felley, J., Vecchione, M., Roper, C. F. E., Sweeney, M. & Christensen, T., 2001–2003: Current Classification of Recent Cephalopoda. National Museum of Natural History: Department of Systematic Biology: Invertebrate Zoology: Cephalopods Hanlon, Roger; Vecchione, Mike; Allcock, Louise (2018). Octopus, Squid, and Cuttlefish: A Visual, Scientific Guide to the Oceans' Most Advanced Invertebrates. University of Chicago Press. ISBN 978-0-226-45956-1. N. Joan Abbott, Roddy Williamson, Linda Maddock. Cephalopod Neurobiology. Oxford University Press, 1995. ISBN 0-19-854790-0 Marion Nixon & John Z. Young. The brains and lives of Cephalopods. Oxford University Press, 2003. ISBN 0-19-852761-6 Hanlon, Roger T. & John B. Messenger. Cephalopod Behaviour. Cambridge University Press, 1996. ISBN 0-521-42083-0 Martin Stevens & Sami Merilaita. Animal camouflage: mechanisms and function. Cambridge University Press, 2011. ISBN 0-521-19911-5 Rodhouse, P. G.; Nigmatullin, Ch. M. (1996). "Role as Consumers". Philosophical Transactions of the Royal Society B: Biological Sciences. 351 (1343): 1003–1022.
Sources: en.wikipedia.org
Vanguard S&P Small-Cap 600 ETF (NYSE Arca: VIOO) SPDR Portfolio S&P 600 Small Cap ETF (NYSE Arca: SPSM) iShares Core S&P Small-Cap ETF (NYSE Arca: IJR) These index funds may be reconstituted at different intervals resulting in a small difference in holdings.
Some 450 species of snake are venomous. Snake venom is produced by glands below the eye (the mandibular glands) and delivered to the target through tubular or channeled fangs. Snake venoms contain a variety of peptide toxins, including proteases, which hydrolyze protein peptide bonds; nucleases, which hydrolyze the phosphodiester bonds of DNA; and neurotoxins, which disrupt signalling in the nervous system. Snake venom causes symptoms including pain, swelling, tissue necrosis, low blood pressure, convulsions, haemorrhage (varying by species of snake), respiratory paralysis, kidney failure, coma, and death. Snake venom may have originated with duplication of genes that had been expressed in the salivary glands of ancestors. Venom is found in a few other reptiles such as the Mexican beaded lizard, the gila monster, and some monitor lizards, including the Komodo dragon. Mass spectrometry showed that the mixture of proteins present in their venom is as complex as the mixture of proteins found in snake venom. Some lizards possess a venom gland; they form a hypothetical clade, Toxicofera, containing the suborders Serpentes and Iguania and the families Varanidae, Anguidae, and Helodermatidae.
=== Overall survival === Overall survival is based on death from any cause, not just the condition being treated, thus it picks up death from side effects of the treatment, and effects on survival after relapse.
2002 Winter Olympic bid scandal – a number of IOC members were forced to resign after it was uncovered that they had accepted inappropriately valuable "gifts" in return for voting for Salt Lake City to hold the Games. 2002 Winter Olympics figure skating scandal – dual gold medals were awarded in pairs figure skating to Canadian pair Jamie Salé and David Pelletier, as well as to Russian pair Elena Berezhnaya and Anton Sikharulidze, after allegations of collusion among judges. Lochtegate – four United States swimmers at the 2016 Summer Olympics including Ryan Lochte were involved in a scandal around an accusation being victims of armed robbery, which ultimately concluded with fines, loss of sponsorships, and statements of apology from the swimmers and various oversight organizations. Russian doping scandal – Russia has the most (51) Olympic medals stripped for doping violations – four times the number of the second country (Belarus). From 2011 to 2015, more than a thousand Russian competitors in various sports, including summer, winter, and Paralympic sports, benefited from a cover-up with no indication that the program has ceased since then.
=== FDA warning letters === During the 21st century, the FDA issued multiple warning letters to American manufacturers of yohimbe supplements for making false health claims and interstate marketing of such products as misbranded, unapproved drugs.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.